









Markets
/
Stocks
/
nasdaq-asmb
/

Assembly Biosciences Inc

ASMB

31.228USD

+0.018+0.06%

Market hours （ET）Quotes delayed by 15 min

239.59MMarket Cap

LossP/E TTM



Assembly Biosciences Inc

31.228

+0.018+0.06%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Assembly Biosciences Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Assembly Biosciences Inc's Score

Industry at a Glance

Industry Ranking

49 / 407

Overall Ranking

153 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

38.200

Target Price

+18.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Assembly Biosciences Inc Highlights

StrengthsRisks

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.

Growing

The company is in a growing phase, with the latest annual income totaling USD 28.52M.

Undervalued

The company’s latest PE is -5.61, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.12M shares, increasing 34.47% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 253.82K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 8.20, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 9.63M, representing a year-over-year increase of 12.81%, while its net profit experienced a year-over-year increase of 8.55%.

Score

Industry at a Glance

Previous score

8.20

Change



Financials

5.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.86

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.91

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.47

Key Metrics

Free cash flow

No Data

Assembly Biosciences Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.43, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -5.61, which is -92.59% below the recent high of -0.42 and -2.88% above the recent low of -5.77.

Score

Industry at a Glance

Previous score

6.43

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 49/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.80, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Assembly Biosciences Inc is 38.00, with a high of 50.00 and a low of 29.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

38.200

Target Price

+18.97%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Assembly Biosciences Inc

ASMB

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 9.10, which is higher than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 34.02 and the support level at 27.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.49

Change

-0.39

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.124

Buy

RSI(14)

62.415

Neutral

STOCH(KDJ)(9,3,3)

73.384

Neutral

ATR(14)

1.713

High Vlolatility

CCI(14)

81.335

Neutral

Williams %R

26.203

Buy

TRIX(12,20)

0.895

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

31.394

Sell

MA10

30.801

Buy

MA20

29.619

Buy

MA50

26.183

Buy

MA100

23.246

Buy

MA200

17.835

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 23.51%, representing a quarter-over-quarter decrease of 54.71%. The largest institutional shareholder is The Vanguard, holding a total of 253.82K shares, representing 1.91% of shares outstanding, with 28.81% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gilead Sciences Inc

4.51M

+103.91%

Farallon Capital Management, L.L.C.

1.14M

Commodore Capital LP

1.00M

Schornstein (Alexander)

543.52K

-25.35%

The Vanguard Group, Inc.

Star Investors

253.82K

+17.52%

B Group, Inc.

189.35K

-5.33%

Renaissance Technologies LLC

Star Investors

107.52K

-5.11%

BlackRock Institutional Trust Company, N.A.

84.00K

+16.72%

Geode Capital Management, L.L.C.

51.02K

+6.94%

Monimus Capital Management, LP

42.07K

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 3.77, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.